Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series
Metrics: PDF 123 views | ?
1Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA
2Ashion Analytics, LLC, Phoenix, AZ 85004, USA
3HonorHealth Research Institute, Scottsdale, AZ 85258, USA
*These authors contributed equally to this work
Published: October 20, 2022
Copyright: © 2022 Drenner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Consent was added to this article: The study, protocol # HRI-0029 is an IRB approved clinical study, WIRB # 20182804, and all patients signed informed consent to participate.
Original article: Oncotarget. 2021; 12:1836–1847. DOI: https://doi.org/10.18632/oncotarget.28046
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.